Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.

Orazio Caffo,Michele Aieta,Erica Palesandro,Marianna Macerelli,Claudia Mucciarini,Maurizio Nicodemo,Ugo De Giorgi,Donata Sartori,Lucia Fratino,Roberto Iacovelli,Sabrina Rossetti,Daniela Scapoli,Franco Morelli,Francesco Carrozza,Franco Nolè,Vittorina Zagonel,Carlo Messina,Donatello Gasparro

Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.

2020

Orazio Caffo
Michele Aieta
Erica Palesandro
Marianna Macerelli
Claudia Mucciarini
Maurizio Nicodemo
Ugo De Giorgi
Donata Sartori
Lucia Fratino
Roberto Iacovelli
Sabrina Rossetti
Daniela Scapoli
Franco Morelli
Francesco Carrozza
Franco Nolè
Vittorina Zagonel
Carlo Messina
Donatello Gasparro

123Background: CHEIRON trial was a phase II study which randomized previously untreated mCRPC pts to receive D 75 mg/m2 IV d1 q3w for 8 courses alone or plus E 160 mg PO daily. As per protocol, E w...

Keywords:

Castration
Oncology
Prostate cancer
Pathology
Docetaxel
Internal medicine
Medicine
first line
Enzalutamide
Phases of clinical research
re challenge
castration resistant
second line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations